MELISSA GUILBEAU: Open Payments
NPI 1952407728 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$32,311 in 220 payments from 21 companies in 2025. Trend: 2023 $45,705 · 2024 $30,422 · 2025 $32,311
Speaker / faculty: $27,000Food & beverage: $3,959Travel & lodging: $1,240Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 69 | $29,120 |
| Braeburn Inc. | 19 | $445 |
| Axsome Therapeutics, Inc. | 7 | $334 |
| Otsuka America Pharmaceutical, Inc. | 21 | $313 |
| E.R. Squibb & Sons, L.L.C. | 8 | $305 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $297 |
| Teva Pharmaceuticals USA, Inc. | 9 | $260 |
| Alkermes, Inc. | 16 | $229 |
| Neurocrine BioSciences, Inc. | 14 | $206 |
| Indivior Inc. | 5 | $159 |
Products named: VRAYLAR, BRIXADI, Auvelity, COBENFY, CAPLYTA, INGREZZA, REXULTI, ARISTADA.
Industry payments across LA — which companies pay providers there.
